Keytruda (generic name: pembrolizumab) is a monoclonal antibody immunotherapy drug developed by Merck, approved by India's Central Drugs Standard Control Organization (CDSCO) in 2019 for multiple cancers including non-small cell lung cancer, head and neck squamous cell carcinoma, and melanoma. It functions by inhibiting the PD-1 receptor, enhancing the immune system's ability to detect and destroy cancer cells. Keytruda's introduction marks a significant advancement in India's oncology treatment landscape due to its targeted mechanism and improved survival outcomes demonstrated in global clinical trials such as the KEYNOTE studies. However, its annual treatment cost of INR 30-40 lakh per patient places it beyond the reach of most Indian patients, exposing systemic challenges in drug affordability and healthcare access.

Pharmacological Profile and Clinical Significance of Keytruda

Keytruda is an immune checkpoint inhibitor targeting the programmed death-1 (PD-1) receptor on T-cells, preventing cancer cells from evading immune detection. Approved by CDSCO in 2019, it is indicated for advanced cancers with poor prognosis under conventional chemotherapy. Clinical trials (KEYNOTE series, 2022) show a 15-20% improvement in survival rates for advanced non-small cell lung cancer patients receiving Keytruda, a substantial gain over standard treatments. Despite its efficacy, immunotherapy like Keytruda is accessible to only 5-10% of Indian cancer patients due to cost and infrastructure limitations (Indian Express, 2024).

• Mechanism: PD-1 receptor blockade enhances T-cell mediated anti-tumor response.
• Indications: Lung cancer, head and neck cancer, melanoma, among others.
• Survival benefit: 15-20% improvement in 5-year survival for advanced lung cancer.
• Access: Limited to 5-10% of patients due to cost and healthcare infrastructure.

Regulatory and Legal Framework Governing Keytruda in India

The Drugs and Cosmetics Act, 1940 governs the approval, import, and manufacture of drugs like Keytruda in India. CDSCO acts as the central regulatory authority for clinical trials and market authorization. The National Pharmaceutical Pricing Authority (NPPA), under the Drug Price Control Order (DPCO), 2013, regulates prices of essential medicines but currently Keytruda is not price-controlled due to its classification and novelty. The Clinical Establishments (Registration and Regulation) Act, 2010 ensures minimum standards in healthcare facilities administering such therapies. The Supreme Court in Swasthya Adhikar Manch v. Union of India (2013) emphasized the constitutional right to affordable healthcare under Article 21, underscoring the state's obligation to regulate drug prices and ensure access.

• Drugs and Cosmetics Act, 1940: Drug approval and import regulation.
• CDSCO: Drug approval authority for immunotherapies.
• NPPA & DPCO 2013: Price regulation, Keytruda currently exempt.
• Clinical Establishments Act, 2010: Regulates healthcare facility standards.
• Article 21 & Supreme Court rulings: Right to health and affordable medicines.

Economic Dimensions: Pricing, Market, and Insurance Coverage

India's oncology drug market was valued at USD 2.3 billion in 2023 with a projected CAGR of 12% till 2028 (Frost & Sullivan, 2024). Keytruda's annual cost (INR 30-40 lakh) far exceeds average Indian healthcare spending, where government health expenditure is only 1.3% of GDP (Economic Survey 2023-24). Over 70% of cancer treatment costs are out-of-pocket (National Health Accounts, 2021), exacerbating financial hardship. Although the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PMJAY) covers some cancer therapies, Keytruda is not widely included due to its cost and lack of price negotiation. India imports over 60% of oncology drugs, including immunotherapies, highlighting dependence on foreign pharmaceutical firms (Pharmaceutical Export Promotion Council, 2023).

• Oncology drug market: USD 2.3 billion in 2023, 12% CAGR till 2028.
• Keytruda cost: INR 30-40 lakh annually per patient.
• Government health expenditure: 1.3% of GDP limits public cancer care funding.
• Out-of-pocket expenditure: >70% for cancer treatment.
• Ayushman Bharat: Covers some cancers but excludes most immunotherapies.
• Imports: 60%+ of oncology drugs are imported.

Institutional Roles in Cancer Treatment and Drug Access

The Indian Council of Medical Research (ICMR) leads cancer epidemiology and clinical trials, including immunotherapy research. The NPPA regulates drug prices but lacks mechanisms for high-cost immunotherapies. The CDSCO approves drugs like Keytruda but does not control pricing. NABH accredits cancer care centers ensuring quality standards. PMJAY provides insurance coverage but has limited inclusion of immunotherapies. The World Health Organization (WHO) offers global cancer control frameworks that India partially adopts.

• ICMR: Cancer research and clinical trials.
• NPPA: Drug price regulation, limited for immunotherapies.
• CDSCO: Drug approval authority.
• NABH: Quality accreditation of cancer centers.
• PMJAY: Health insurance, limited immunotherapy coverage.
• WHO: Provides cancer control guidelines.

Comparative Analysis: India vs United Kingdom on Immunotherapy Access

Policy Gaps and Challenges in India's Immunotherapy Access

India lacks a national immunotherapy access policy and structured price negotiation framework, resulting in prohibitively high costs. Insurance schemes like Ayushman Bharat exclude most high-cost immunotherapies. Infrastructure deficits in cancer centers, limited NABH accreditation, and low public health spending compound access issues. The dependence on imported oncology drugs increases vulnerability to global price fluctuations. These gaps restrict equitable access to transformative cancer treatments like Keytruda, undermining India's commitment to the right to health under Article 21.

• No comprehensive immunotherapy access policy or price negotiation.
• Limited insurance coverage for high-cost drugs.
• Infrastructure and quality accreditation gaps.
• High import dependence increases cost volatility.
• Low public health expenditure limits affordability.

Significance and Way Forward

• Develop a national immunotherapy policy integrating price negotiation and inclusion under Ayushman Bharat.
• Expand NPPA’s mandate to regulate prices of novel oncology drugs.
• Boost public health expenditure to improve cancer care infrastructure and insurance coverage.
• Promote domestic pharmaceutical R&D to reduce import dependence.
• Strengthen NABH accreditation to ensure quality immunotherapy delivery.
• Leverage WHO frameworks for comprehensive cancer control strategies.

Jharkhand & JPSC Relevance

• JPSC Paper: Paper 2 (Health and Social Welfare)
• Jharkhand Angle: Rising cancer incidence in Jharkhand with limited access to advanced therapies like immunotherapy; state healthcare infrastructure constraints.
• Mains Pointer: Frame answers highlighting state-level healthcare gaps, the need for affordable cancer care, and integration of national schemes like Ayushman Bharat with local health policies.